Home/Pipeline/Tiotropium/Olodaterol (Spiolto)

Tiotropium/Olodaterol (Spiolto)

COPD

ApprovedCommercial

Key Facts

Indication

COPD

Phase

Approved

Status

Commercial

Company

KYORIN Pharmaceutical

About KYORIN Pharmaceutical

KYORIN Pharmaceutical is a mid-sized, revenue-generating Japanese pharmaceutical company with a diversified portfolio spanning prescription drugs, over-the-counter (OTC) products, and veterinary medicines. The company leverages its expertise in respiratory and urological diseases to maintain a stable revenue base from commercial products while investing in R&D for future growth. Its strategic focus includes lifecycle management of key brands and advancing its pipeline through internal research and selective partnerships.

View full company profile

Therapeutic Areas

Respiratory Urology Otolaryngology Gastroenterology Dermatology

Other COPD Drugs

Drug	Company	Phase	Status
Breztri	AstraZeneca	Approved	Commercial
Dupixent	Regeneron Pharmaceuticals	Phase 3	Active
Generic Spiriva (Tiotropium)	Lupin Limited	Approved	Commercial
Brovana (arformoterol tartrate)	Bausch Health	Approved	Commercial
GB-0895	Generate Biomedicines	Phase 1	Active - Evaluating safety, PK, and PD
Yupelri® (revefenacin)	Cleo Life Sciences	Approved	Supported early development CMC